Argo Biopharma announced that the Phase 1 clinical trial application for its second independently developed siRNA drug has received HREC approval. The Phase 1 clinical study is scheduled to begin in Australia shortly. Notably, this is another novel siRNA drug approved for clinical study in less than two months, following the approval of the first siRNA drug for clinical study in Australia.

As a novel class of drugs emerged in recent years, siRNA drugs have the advantages of multiple druggable targets, high efficacy, excellent safety, and low dosing frequency. Additionally, they have a broad range of indications, which makes them one of the world's frontier medical fields with the most potential for development.

Argo Biopharma was established in 2021 by several returnee scientists with rich experience in the field of siRNA drug development. The company is dedicated to developing a new generation of siRNA drugs to provide better treatments for patients around the world.

Argo Biopharma announced in May 2021 that it had closed an angel round financing nearly 5 million US dollars, with Apricot Capital exclusively leading the investment. In March 2022, Argo Biopharma once again announced the completion of a series A financing of US $63 million, led by Loyal Valley Capital, and co-invested by CPE fund, TAO CAPITAL, Trinity Fund, and GSR United Capital.

The approval of the clinical study application for its second siRNA drug is another very significant milestone for Argo BioPharma. Argo Biopharma is now actively advancing multiple preclinical R&D pipelines, and several of which are nearing IND-enabling status. It is anticipated that more clinical phase 1 pipelines will receive approval for clinical study by 2023.